Gene

PRKDC

protein kinase, DNA-activated, catalytic subunit

Explore in graph →CI-GENE-00021016HGNC:9413 ENSG00000253729 NCBI 5591 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (3)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PRKDC Mutation3
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	3	submitted	EID11979 This gene was identified as recurrently mutated in an analysis of 574 DLBCL exomes PMID 29641966 · Schmitz et al., 2018 · Open in CIViC	civic
Anti-CTLA-4 Monoclonal Antibody	Melanoma	Predictive	B	Supports Sensitivity Response	2	accepted	EID13226 In a retrospective analysis of the Allen cohort of 110 patients with advanced melanoma treated with CTLA-4 blockade, 9 patients with nonsynonymous PRKDC mutations had a higher objective response rate … (full text at CIViC) PMID 32502294 · Chen et al., 2020 · Open in CIViC

Cohorts

Alteration frequency by cohort (116)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved116 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Cutaneous Squamous Cell Carcinoma (DFCI, Clin Cancer Res 2015) cscc_dfarber_2015	Skin Squamous Cell Carcinoma	Ssm

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.
· Mol Oncol · 2020 · PMID 32502294 · validated civic_curation pubmed